Imfinzi

Drug Celgene Corporation
Total Payments
$3.2M
Transactions
142
Doctors
0
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2019 $966,511 66 0
2018 $2.2M 76 0

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $3.2M 142 100.0%

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
MEDI4736-DLBCL-001 - A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma Celgene Corporation $604,366 0
MEDI4736-MDS-001 - An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patient Celgene Corporation $385,467 0
MEDl-4736-NHL-001 - A Phase Ib multicenter, open-label study to determine the recommended dose and regimen of durvalumab in combination with lenalidomide with and without low-dose dexamethasone in subjects with newly dia Celgene Corporation $360,815 0
A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma (MEDI4736-DLBCL-001) Celgene Corporation $313,712 0
MEDl-4736-MM-001 - A Phase Ib multicenter, open-label study to determine the recommended dose and regimen of durvalumab in combination with lenalidomide with and without low-dose dexamethasone in subjects with newly dia Celgene Corporation $223,144 0
An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML) (MEDI4736-MDS-001) Celgene Corporation $217,600 0
MEDI4736-MM-005 - MEDI4736-MM-005 (FUSION MM-005): A Phase 2, Multicenter, Single-Arm, Study to Determine the Efficacy for the Combination of Durvalumab (DURVA) plus Daratumumab (DARA) (D2) in Subjects with Relapsed a Celgene Corporation $200,408 0
MEDI-4736-MM-003 - A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects With Relapsed and Refractory Multiple M Celgene Corporation $160,075 0
DV-CL-HL-PI-008000 - P 1/2A STUDY OF ANTI-PD-L1 MONOCLONAL ANTIBODY DURVALUMAB/PRALATREXATE/ROMIDEPSIN, ORAL 5-AZACITIDINE/ROMIDEPSIN, OR ROMIDEPSIN ALONE FOR THE TREATMENT OF PTS WITH RELAPSED AND/OR REFRACTORY LYMPHOID Celgene Corporation $126,285 0
A Phase Ib multicenter, open-label study to determine the recommended dose and regimen of durvalumab in combination with lenalidomide with and without low-dose dexamethasone in subjects with newly diagnosed multiple myeloma (MEDl-4736-MM-001) Celgene Corporation $108,303 0
MEDI-4736-MM-002 - A Phase Ib multicenter, open-label study to determine the recommended dose and regimen of durvalumab in combination with lenalidomide with and without low-dose dexamethasone in subjects with newly dia Celgene Corporation $97,376 0
A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma (FUSIONMM-003) (MEDI4736-MM-003) Celgene Corporation $77,665 0
A Phase Ib multicenter, open-label study to determine the recommended dose and regimen of durvalumab in combination with lenalidomide with and without low-dose dexamethasone in subjects with newly diagnosed multiple myeloma (MEDl-4736-NHL-001) Celgene Corporation $59,399 0
A Phase 1/2, Open-label, Multi-center Study to Assess the Safety and Tolerability of Durvalumab (Anti-PDL1 Antibody) as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocitic Leukemia (MEDI4736-NHL-001) Celgene Corporation $59,345 0
P 1/2A STUDY OF ANTI-PD-L1 MONOCLONAL ANTIBODY DURVALUMAB/PRALATREXATE/ROMIDEPSIN, ORAL 5-AZACITIDINE/ROMIDEPSIN, OR ROMIDEPSIN ALONE FOR THE TREATMENT OF PTS WITH RELAPSED AND/OR REFRACTORY LYMPHOID MALIGNANCIES (DV-CL-HL-PI-008000) Celgene Corporation $56,218 0
A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (MEDI-4736-MM-003) Celgene Corporation $50,195 0
DV-CL-AML-PI-12849 - Phase II Study of 7+3 Followed by Durvalumab in Newly Diagnosed Adverse-Risk AML Celgene Corporation $21,623 0
MEDI4736-NHL-002 - A Phase 2, Multicenter, Open-label Study to Determine the Efficacy and Safety of Durvalumab in Subjects with Relapsed or Refractory Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or Acute Lymphobl Celgene Corporation $17,500 0
A Phase IB Multicenter, Open-label Study To Determine The Recommended Dose And Regimen Of Durvalumab (MEDI4736) Either As Monotherapy or In Combination With Pomalidomide (POM) With Or Without Low-Dose Dexamethasone (DEX) In Subjects With Relapsed And Refractory Multiple Myeloma (RRMM) (MEDI4736-MM-001) Celgene Corporation $13,228 0
Pilot Trial Evaluating Durvalumab in Combination with Radiotherapy For Patients with Bone Plasmacytoma (DV-CL-PLASM-PI-008059) Celgene Corporation $6,994 0

Top Doctors Receiving Payments for Imfinzi

Doctor Specialty Location Total Records
Unknown — Columbus, OH $3.2M 142

Manufacturing Companies

Product Information

  • Type Drug
  • Total Payments $3.2M
  • Total Doctors 0
  • Transactions 142

About Imfinzi

Imfinzi is a drug associated with $3.2M in payments to 0 healthcare providers, recorded across 142 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.

Payment data is available from 2018 to 2019. In 2019, $966,511 was paid across 66 transactions to 0 doctors.

The most common payment nature for Imfinzi is "Unspecified" ($3.2M, 100.0% of total).

Imfinzi is associated with 20 research studies, including "MEDI4736-DLBCL-001 - A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma" ($604,366).